Operating Segments (Tables)

9 Months Ended

Sep. 30, 2016

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended September 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	2,959,254		$	3,879,675
BioTherapeutics		-			-
Total	$	2,959,254		$	3,879,675
Income (Loss) from Operations
Vaccines/BioDefense	$	239,012		$	653,415
BioTherapeutics		(908,086	)		(959,065	)
Corporate		(829,743	)		(964,016	)
Total	$	(1,498,817	)	$	(1,269,666	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,090		$	10,093
BioTherapeutics		10,313			50,673
Corporate		2,063			2,074
Total	$	22,466		$	62,840
Other Income (Expense), Net
Corporate	$	(174,400	)	$	4,044,014
Share-Based Compensation
Vaccines/BioDefense	$	25,164		$	19,344
BioTherapeutics		30,496			29,180
Corporate		61,590			86,400
Total	$	117,250		$	134,924

	Nine Months Ended September 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	8,750,291		$	5,781,816
BioTherapeutics		-			13,972
Total	$	8,750,291		$	5,795,788
Income (Loss) from Operations
Vaccines/BioDefense	$	1,291,123		$	1,040,627
BioTherapeutics		(2,822,766	)		(3,094,883	)
Corporate		(2,882,836	)		(2,808,428	)
Total	$	(4,414,479	)	$	(4,862,684	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	30,150		$	29,820
BioTherapeutics		31,309			148,913
Corporate		6,443			5,763
Total	$	67,902		$	184,496
Other Income (Expense), Net
Corporate	$	1,499,055		$	(909,984	)
Share-Based Compensation
Vaccines/BioDefense	$	77,393		$	63,280
BioTherapeutics		96,313			88,615
Corporate		280,229			262,217
Total	$	453,935		$	414,112

	As of September 30, 2016		As of December 31, 2015
Identifiable Assets
Vaccines/BioDefense	$	1,801,149	$	2,123,676
BioTherapeutics		56,555		76,183
Corporate		5,896,100		5,187,263
Total	$	7,753,804	$	7,387,122